6.
Ai L, Xu A, Xu J
. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. Adv Exp Med Biol. 2020; 1248:33-59.
DOI: 10.1007/978-981-15-3266-5_3.
View
7.
Raulet D
. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003; 3(10):781-90.
DOI: 10.1038/nri1199.
View
8.
Bahram S, Bresnahan M, Geraghty D, Spies T
. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci U S A. 1994; 91(14):6259-63.
PMC: 44180.
DOI: 10.1073/pnas.91.14.6259.
View
9.
Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein K, Spies T
. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A. 1999; 96(12):6879-84.
PMC: 22010.
DOI: 10.1073/pnas.96.12.6879.
View
10.
Stastny P
. Introduction: MICA/MICB in innate immunity, adaptive immunity, autoimmunity, cancer, and in the immune response to transplants. Hum Immunol. 2006; 67(3):141-4.
DOI: 10.1016/j.humimm.2006.02.019.
View
11.
El-Gazzar A, Groh V, Spies T
. Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer. J Immunol. 2013; 191(4):1509-15.
PMC: 3736343.
DOI: 10.4049/jimmunol.1301071.
View
12.
Cosman D, Mullberg J, SUTHERLAND C, Chin W, Armitage R, Fanslow W
. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001; 14(2):123-33.
DOI: 10.1016/s1074-7613(01)00095-4.
View
13.
Mistry A, OCallaghan C
. Regulation of ligands for the activating receptor NKG2D. Immunology. 2007; 121(4):439-47.
PMC: 2265965.
DOI: 10.1111/j.1365-2567.2007.02652.x.
View
15.
Hayakawa Y
. Targeting NKG2D in tumor surveillance. Expert Opin Ther Targets. 2012; 16(6):587-99.
DOI: 10.1517/14728222.2012.681378.
View
16.
Nausch N, Cerwenka A
. NKG2D ligands in tumor immunity. Oncogene. 2008; 27(45):5944-58.
DOI: 10.1038/onc.2008.272.
View
17.
Groh V, Wu J, Yee C, Spies T
. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002; 419(6908):734-8.
DOI: 10.1038/nature01112.
View
18.
Konagai A, Yoshimura K, Hazama S, Yamamoto N, Aoki K, Ueno T
. Correlation Between NKG2DL Expression and Antitumor Effect of Protein-bound Polysaccharide-K in Tumor-bearing Mouse Models. Anticancer Res. 2017; 37(8):4093-4101.
DOI: 10.21873/anticanres.11796.
View
19.
Salih H, Rammensee H, Steinle A
. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol. 2002; 169(8):4098-102.
DOI: 10.4049/jimmunol.169.8.4098.
View
20.
Salih H, Goehlsdorf D, Steinle A
. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum Immunol. 2006; 67(3):188-95.
DOI: 10.1016/j.humimm.2006.02.008.
View
21.
Wu J, Atteridge C, Wang X, Seya T, Plymate S
. Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation. Clin Cancer Res. 2009; 15(2):632-40.
PMC: 2775521.
DOI: 10.1158/1078-0432.CCR-08-1305.
View